Metraipolis › archive › dc_9aaed0741e97
Advancing global health access through market shaping: Cases and learnings — Europe PMC PMID:41734147
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41734147
- DOI
- 10.1371/journal.pgph.0004523
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-06T08:20:14.278Z
- SHA-256 of the archived text
98ef71a53b6420ffaf7b0ca62270703e44ac290cd9489eedb3a26144ad293569- Stable URL of this page
https://metraipolis.com/documento/dc_9aaed0741e97
How to cite
Advancing global health access through market shaping: Cases and learnings — Europe PMC PMID:41734147 — Europe PMC (en), https://europepmc.org/article/MED/41734147 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_9aaed0741e97 (Metraipolis archive dc_9aaed0741e97, sha256 98ef71a53b6420ffaf7b0ca62270703e44ac290cd9489eedb3a26144ad293569)
BibTeX
@misc{dc9aaed0741e97,
title = {Advancing global health access through market shaping: Cases and learnings — Europe PMC PMID:41734147},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41734147},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_9aaed0741e97; sha256 98ef71a53b6420ffaf7b0ca62270703e44ac290cd9489eedb3a26144ad293569},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/41734147. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
New health products have contributed to major improvements in public health, but many clinically effective interventions still face delays in reaching low- and middle-income countries (LMICs). Market shaping approaches have emerged as a set of tools designed to address such access gaps by influencing prices, supply, and demand. Drawing on practitioner experience and illustrative cases, this paper examines how market shaping mechanisms have been used to expand access to pharmaceutical products in LMICs. We review examples including dolutegravir, rifapentine-based tuberculosis preventive therapy, pretomanid for drug-resistant tuberculosis, the RTS,S malaria vaccine, and Rwanda's hepatitis C program, alongside ecosystem-level interventions such as revolving funds and initiatives to strengthen regional manufacturing. Across these cases, we suggest generalizable lessons and describe trade-offs related to donor dependence, supplier concentration, and timing of interventions. The paper identifies priorities for empirical research to assess the performance, risks, and applicability of market shaping tools as global health needs and resource environments evolve. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PLOS global public health, 2026 (prima pubblicazione 2026-02-24). Identificativi: PMID 41734147 · PMCID PMC12931745 · DOI 10.1371/journal.pgph.0004523. Pagina: https://europepmc.org/article/MED/41734147 — https://doi.org/10.1371/journal.pgph.0004523. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-06T08:18:30.472Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.